Prime Medicine Inc (NASDAQ: PRME) on Tuesday, plunged -5.79% from the previous trading day, before settling in for the closing price of $2.42. Within the past 52 weeks, PRME’s price has moved between $2.37 and $9.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -25.00% over the last five years. The company achieved an average annual earnings per share of 26.60%. With a float of $50.89 million, this company’s outstanding shares have now reached $131.16 million.
The firm has a total of 234 workers. Let’s measure their productivity. In terms of profitability, gross margin is 98.47%, operating margin of -586.63%, and the pretax margin is -568.39%.
Prime Medicine Inc (PRME) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Prime Medicine Inc is 61.20%, while institutional ownership is 32.79%. The most recent insider transaction that took place on Feb 15 ’24, was worth 20,000,000. In this transaction Director of this company bought 3,200,000 shares at a rate of $6.25, taking the stock ownership to the 3,200,000 shares. Before that another transaction happened on Feb 15 ’24, when Company’s 10% Owner bought 3,200,000 for $6.25, making the entire transaction worth $20,000,000. This insider now owns 3,200,000 shares in total.
Prime Medicine Inc (PRME) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 26.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.17% during the next five years compared to -193.88% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Prime Medicine Inc (PRME) is currently performing well based on its current performance indicators. A quick ratio of 6.50 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 373.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.01, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Analysing the last 5-days average volume posted by the [Prime Medicine Inc, PRME], we can find that recorded value of 1.16 million was better than the volume posted last year of 0.91 million. As of the previous 9 days, the stock’s Stochastic %D was 4.56%. Additionally, its Average True Range was 0.21.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 0.72%, which indicates a significant decrease from 1.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.18% in the past 14 days, which was lower than the 79.03% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.94, while its 200-day Moving Average is $4.41. Now, the first resistance to watch is $2.41. This is followed by the second major resistance level at $2.53. The third major resistance level sits at $2.61. If the price goes on to break the first support level at $2.21, it is likely to go to the next support level at $2.13. Now, if the price goes above the second support level, the third support stands at $2.01.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
Market capitalization of the company is 299.05 million based on 131,161K outstanding shares. Right now, sales total 0 K and income totals -198,130 K. The company made 210 K in profit during its latest quarter, and -52,520 K in sales during its previous quarter.
